Cara Therapeutics Stock Forecast, Price & News

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics or view top-rated stocks.

How has Cara Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CARA shares have decreased by 11.0% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a decrease in short interest during the month of December. As of December 15th, there was short interest totaling 2,070,000 shares, a decrease of 19.8% from the November 30th total of 2,580,000 shares. Based on an average daily volume of 671,200 shares, the short-interest ratio is currently 3.1 days. Currently, 4.7% of the company's stock are sold short.
View Cara Therapeutics' Short Interest.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cara Therapeutics.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to analyst estimates of $15.74 million. During the same period last year, the business posted ($0.35) earnings per share.
View Cara Therapeutics' earnings history.

What price target have analysts set for CARA?

3 brokerages have issued 12-month price targets for Cara Therapeutics' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Cara Therapeutics' stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 114.8% from the stock's current price.
View analysts' price targets for Cara Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:

• Christopher Posner, President, Chief Executive Officer & Director
• Thomas Reilly, Chief Financial & Accounting Officer
• Frèdèrique Menzaghi, Chief Scientific Officer, Senior VP-R&D
• Joana Goncalves, Chief Medical Officer (LinkedIn Profile)
• Scott M. Terrillion, Secretary & Chief Compliance Officer (LinkedIn Profile)

Who are some of Cara Therapeutics' key competitors?

Some companies that are related to Cara Therapeutics include Aurinia Pharmaceuticals (AUPH), Sage Therapeutics (SAGE), Arcus Biosciences (RCUS), Mawson Infrastructure Group (WIZP), ChemoCentryx (CCXI), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Schrödinger (SDGR), Indivior (INVVY), Xencor (XNCR), Harmony Biosciences (HRMY), Corcept Therapeutics (CORT), 23andMe (ME), Cryoport (CYRX) and Ligand Pharmaceuticals (LGND).
View all of CARA's competitors.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Patriot Financial Group Insurance Agency LLC (0.08%) and Baldwin Brothers LLC MA (0.02%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers LLC MA. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion, and Thomas Charles Reilly.
View insider buying and selling activity for Cara Therapeutics or view top insider-selling stocks.

Which major investors are buying Cara Therapeutics stock?

CARA stock was acquired by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Cara Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $11.95.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $638.84 million and generates $135.08 million in revenue each year. The biopharmaceutical company earns $8.41 million in net income (profit) each year or $0.49 on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 80 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

Where are Cara Therapeutics' headquarters?

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at [email protected], or via fax at 203-567-1510.